Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2016, Article ID 4108490, 7 pages
http://dx.doi.org/10.1155/2016/4108490
Clinical Study

Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy

1Department of Ophthalmology, Ruijin Hospital, School of Medicine, The Jiaotong University, Shanghai 200025, China
2Department of Ophthalmology, Ruijin Hospital, Luwan Branch, School of Medicine, The Jiaotong University, Shanghai 200025, China
3Department of Ophthalmology, The Affiliated Hospital, School of Medicine, Ningbo University, Ningbo, Zhejiang 310000, China

Received 25 December 2015; Revised 26 March 2016; Accepted 27 April 2016

Academic Editor: Paolo Lanzetta

Copyright © 2016 Xi Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. P. Schachat, R. T. Oyakawa, R. G. Michels, and T. A. Rice, “Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications,” Ophthalmology, vol. 90, no. 5, pp. 522–530, 1983. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Soto-Pedre, M. C. Hernaez-Ortega, and J. A. Vazquez, “Risk factors for postoperative hemorrhage after vitrectomy for diabetic retinopathy,” Ophthalmic Epidemiology, vol. 12, no. 5, pp. 335–341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. P.-T. Yeh, C.-M. Yang, C.-H. Yang, and J.-S. Huang, “Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage: an ultrasound biomicroscopy study,” Ophthalmology, vol. 112, no. 12, pp. 2095–2102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. G. C. Brown, W. S. Tasman, W. E. Benson, J. A. McNamara, and R. C. Eagle Jr., “Reoperation following diabetic vitrectomy,” Archives of Ophthalmology, vol. 110, no. 4, pp. 506–510, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Goto, M. Inatani, T. Inoue et al., “Frequency and risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy,” Journal of Glaucoma, vol. 22, no. 7, pp. 572–576, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. E. Iliev, D. Domig, U. Wolf-Schnurrbursch, S. Wolf, and G.-M. Sarra, “Intravitreal bevacizumab (Avastin®) in the treatment of neovascular glaucoma,” American Journal of Ophthalmology, vol. 142, no. 6, pp. 1054–1056, 2006. View at Publisher · View at Google Scholar
  7. J. O. Mason III, M. A. Albert Jr., A. Mays, and R. Vail, “Regression of neovascular iris vessels by intravitreal injection of bevacizumab,” Retina, vol. 26, no. 7, pp. 839–841, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. SooHoo, L. K. Seibold, and M. Y. Kahook, “Recent advances in the management of neovascular glaucoma,” Seminars in Ophthalmology, vol. 28, no. 3, pp. 165–172, 2013. View at Publisher · View at Google Scholar
  9. J. Lüke, K. Nassar, M. Lüke, and S. Grisanti, “Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma—results from a prospective interventional case series,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 251, no. 10, pp. 2403–2413, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Pokroy, Y. Greenwald, A. Pollack, A. Bukelman, and M. Zalish, “Visual loss after transscleral diode laser cyclophotocoagulation for primary open-angle and neovascular glaucoma,” Ophthalmic Surgery Lasers and Imaging, vol. 39, no. 1, pp. 22–29, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Ghosh, D. Singh, J. B. Ruddle, M. Shiu, M. A. Coote, and J. G. Crowston, “Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin) in neovascular glaucoma,” Clinical and Experimental Ophthalmology, vol. 38, no. 4, pp. 353–357, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Wakabayashi, Y. Usui, Y. Okunuki et al., “Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy,” Investigative Ophthalmology & Visual Science, vol. 53, no. 10, pp. 6403–6410, 2012. View at Google Scholar
  13. P.-T. Yeh, C.-H. Yang, and C.-M. Yang, “Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy,” Acta Ophthalmologica, vol. 89, no. 7, pp. 634–640, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Cheng, X.-H. Liu, X. Shen, and Y.-S. Zhong, “Ahmed valve implantation for neovascular glaucoma after 23-gauge vitrectomy in eyes with proliferative diabetic retinopathy,” International Journal of Ophthalmology, vol. 6, no. 3, pp. 316–320, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. T. Holladay, “Proper method for calculating average visual acuity,” Journal of Refractive Surgery, vol. 13, no. 4, pp. 388–391, 1997. View at Google Scholar · View at Scopus
  16. C.-M. Yang, P.-T. Yeh, and C.-H. Yang, “Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy,” Ophthalmology, vol. 114, no. 4, pp. 710–715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. D. H. W. Steel, M. S. Habib, S. Park, A. J. Hildreth, and R. I. Owen, “Entry site neovascularization and vitreous cavity hemorrhage after diabetic vitrectomy. The predictive value of inner sclerostomy site ultrasonography,” Ophthalmology, vol. 115, no. 3, pp. 525–532, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Blumenkranz, T. Gardner, and G. Blankenship, “Fluid-gas exchange and photocoagulation after vitrectomy. Indications, technique, and results,” Archives of Ophthalmology, vol. 104, no. 2, pp. 291–296, 1986. View at Publisher · View at Google Scholar · View at Scopus
  19. R. L. Avery, J. Pearlman, D. J. Pieramici et al., “Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy,” Ophthalmology, vol. 113, no. 10, pp. 1695–1705.e6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. T. W. Isaacs and C. Barry, “Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin),” Clinical and Experimental Ophthalmology, vol. 34, no. 8, pp. 802–803, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Minnella, C. M. Savastano, L. Ziccardi et al., “Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy,” Acta Ophthalmologica, vol. 86, no. 6, pp. 683–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Ruiz-Moreno, J. A. Montero, F. Lugo, P. Amat, and C. Staicu, “Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy,” Acta Ophthalmologica, vol. 86, no. 2, pp. 231–232, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. X.-J. Li, X.-P. Yang, Q.-M. Li, Y.-Y. Wang, and X.-B. Lyu, “Ranibizumab plus combined surgery for treatment of neovascular glaucoma with vitreous hemorrhage,” Chinese Medical Journal, vol. 128, no. 15, pp. 2078–2083, 2015. View at Publisher · View at Google Scholar · View at Scopus